A Phase 1, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB067 Administered to Adult Subjects With Amyotrophic Lateral Sclerosis
Phase of Trial: Phase I/II
Latest Information Update: 16 Jun 2017
At a glance
- Drugs ISIS SOD1Rx (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Biogen
- 27 Mar 2017 Planned End Date changed from 1 Apr 2018 to 1 Jul 2018.
- 27 Mar 2017 Planned primary completion date changed from 1 Apr 2018 to 1 Jul 2018.
- 11 Dec 2015 Status changed from not yet recruiting to recruiting, according to an Isis Pharmaceuticals media release.